Roya Amini-Naieni
CEO

Trilobio provides an accessible platform for full laboratory automation, integrating robotics, modular tools, and intuitive software for biological experimentation. This system enables researchers to design and execute complex protocols quickly without extensive coding or calibration. The platform delivers precise, reproducible results while allowing labs to scale capacity affordably by connecting modular components.
Raised to date
$3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.





Traditional lab technologies often lag behind the rapid advancements in biology, creating bottlenecks in research and development. The manual and semi-automated processes common in many labs are time-consuming, prone to errors, and difficult to scale, hindering innovation in genetic engineering, molecular biology, and synthetic biology.
Trilobio offers a fully automated biology platform that integrates robotics, hardware, and software to streamline and accelerate lab processes. The platform centers around the Trilobot, a self-calibrating robot capable of performing a wide range of tasks through interchangeable tools. Trilobio OS, the platform's software, allows researchers to design and execute experiments, manage lab resources, and automatically document research. By automating repetitive tasks and optimizing workflows, Trilobio enables researchers to focus on experimental design and data analysis, increasing throughput and reproducibility.
The primary target audience includes researchers and teams in genetic engineering, molecular biology, synthetic biology, microbiology, and biochemistry within academic research, therapeutics, and biotech companies.